DFX Intelligence

Data Factory

Private equityFirmbuyoutmiddle market

RP Management, LLC

Private Equity

New York, NY

We are the world’s largest buyer of biopharmaceutical royalties and a leading funder of innovation in life sciences.

This is the graph view. The full profile, with its team, deals and sources, is on Private Equity.Open the full profile →

Search this name across graphsid dfx:pe:beeb1906-0be1-473e-ba25-2a1103ff23e3

Data as of Sep 15, 2026 (this record's last observation) from federal regulator filings, firm and issuer disclosures. Page built Sep 19, 2026, 9:21 AM UTC and rebuilt at most every 15 minutes.

Relationships: 95
Dated events: 36
On other graphs: 1
Observed: Sep 13, 2026 to Sep 15, 2026
31 observations

Across DFX

same identity by shared identifier, citation, or a bridge measured by hand

RIA / Wealth Managementidentity

RP MANAGEMENT, LLC

Registered adviser · shared crd

Facts

fact = as filed or announced; derived = computed by DFX; estimate = a band, never a point

Funds: 19
PE funds: 18
Vintages: 2008 to 2021
PE GAV, 2024 filing: $1.6Bgross asset value on Form ADV; never dry powder
Regulatory AUM: $18B
Investments: 63
Active investments: 0
Size band: MIDDLE MARKETderivedproxy: $1.62bn Private Equity Fund GAV on the Form ADV filed 2024-03-28
Stated sectors: life_sciences
Latest ADV filing: Mar 28, 2024
Employees (ADV): 86
Website: royaltypharma.com

Funds

Fund	Vintage	Lifecycle	ADV type	Form D sold	GAV
RPI Intermediate Finance Trust	2021	Unknown	Hedge Fund	n/a	$1.5B
Royalty Pharma Select	2021	Unknown	Private Equity Fund	n/a	$0
RPI International Partners 2019, LP	2019	Harvest	Private Equity Fund	n/a	$20.2M
RPI US Partners 2019, LP	2019	Mature	Private Equity Fund	n/a	$1.6B
RPI International Holdings 2019, LP	2019	Unknown	Private Equity Fund	n/a	$1.0B
RPS Biopharma Investments, LP	2018	Unknown	Private Equity Fund	n/a	$29.6M
RPS Biopharma Holdings, L.P.	2018	Unknown	Private Equity Fund	n/a	$32.8M
Royalty Pharma Cayman Holdings 2008, LP	2008	Harvest	Private Equity Fund	n/a	$724,936
Royalty Pharma US Partners 2008, LP	2008	Harvest	Private Equity Fund	n/a	$1.5M
Royalty Pharma Cayman Partners 2008, LP	2008	Harvest	Private Equity Fund	n/a	$724,936
RPI US Partners, LP	n/a	Unknown	Private Equity Fund	n/a	$858M
Royalty Pharma US Partners LP	n/a	Harvest	Private Equity Fund	n/a	$20.6M
RPI International Partners II, LP	n/a	Unknown	Private Equity Fund	n/a	$344M
Royalty Pharma Cayman Holdings, LP	n/a	Harvest	Private Equity Fund	n/a	$61.9M
RPI International Holdings, LP	n/a	Unknown	Private Equity Fund	n/a	$2.1B
RPI International Partners, LP	n/a	Unknown	Private Equity Fund	n/a	$1.8B
Royalty Pharma Cayman Partners, LP	n/a	Harvest	Private Equity Fund	n/a	$61.9M
RPI Holdings, LP	n/a	Wound down	Private Equity Fund	n/a	$1.1B
RPI US Partners II, LP	n/a	Unknown	Private Equity Fund	n/a	$415M

Investments

Company	State	Role	Control	Invested	Exited	Status
Mimrylo	n/a	unknown	unknown	n/a	n/a	unknown
cliramitug	n/a	unknown	unknown	n/a	n/a	unknown
JNJ-4804	n/a	unknown	unknown	n/a	n/a	unknown
Ziihera	n/a	unknown	unknown	n/a	n/a	unknown
TEV-‘408	n/a	unknown	unknown	n/a	n/a	unknown
Evrysdi	n/a	unknown	unknown	n/a	n/a	unknown
Jideytro	n/a	unknown	unknown	n/a	n/a	unknown
neladalkib	n/a	unknown	unknown	n/a	n/a	unknown
Avlayah	n/a	unknown	unknown	n/a	n/a	unknown
Amvuttra	n/a	unknown	unknown	n/a	n/a	unknown
obexelimab	n/a	unknown	unknown	n/a	n/a	unknown
Imdelltra	n/a	unknown	unknown	n/a	n/a	unknown
Rasonque	n/a	unknown	unknown	n/a	n/a	unknown
litifilimab	n/a	unknown	unknown	n/a	n/a	unknown
Rytelo	n/a	unknown	unknown	n/a	n/a	unknown
Niktimvo	n/a	unknown	unknown	n/a	n/a	unknown
deucrictibant	n/a	unknown	unknown	n/a	n/a	unknown
Yorvipath	n/a	unknown	unknown	n/a	n/a	unknown
Voranigo	n/a	unknown	unknown	n/a	n/a	unknown
frexalimab	n/a	unknown	unknown	n/a	n/a	unknown
ecopipam	n/a	unknown	unknown	n/a	n/a	unknown
TEV-‘749	n/a	unknown	unknown	n/a	n/a	unknown
Skytrofa	n/a	unknown	unknown	n/a	n/a	unknown
Adstiladrin	n/a	unknown	unknown	n/a	n/a	unknown
Cobenfy	n/a	unknown	unknown	n/a	n/a	unknown
Spinraza	n/a	unknown	unknown	n/a	n/a	unknown
olpasiran	n/a	unknown	unknown	n/a	n/a	unknown
Trelegy Ellipta	n/a	unknown	unknown	n/a	n/a	unknown
Myqorzo	n/a	unknown	unknown	n/a	n/a	unknown
Orladeyo	n/a	unknown	unknown	n/a	n/a	unknown

Relationships

showing 80 of 95

Invested in (63)

→ AirsupraCompanyunknown
factThe subject's own site
→ LetairisCompanyunknown
factThe subject's own site
→ LexiscanCompanyunknown
factThe subject's own site
→ OnglyzaCompanyunknown
factThe subject's own site
→ JanuviaCompanyunknown
factThe subject's own site
→ MirceraCompanyunknown
factThe subject's own site
→ CimziaCompanyunknown
factThe subject's own site
→ imbruvicaCompanyunknown
factThe subject's own site
→ SoliquaCompanyunknown
factThe subject's own site
→ BosulifCompanyunknown
factThe subject's own site
→ XtandiCompanyunknown
factThe subject's own site
→ TysabriCompanyunknown
factThe subject's own site
→ MimryloCompanyunknown
factThe subject's own site
→ cliramitugCompanyunknown
factThe subject's own site
→ JNJ-4804Companyunknown
factThe subject's own site
→ ZiiheraCompanyunknown
factThe subject's own site
→ TEV-‘408Companyunknown
factThe subject's own site
→ EvrysdiCompanyunknown
factThe subject's own site
→ JideytroCompanyunknown
factThe subject's own site
→ neladalkibCompanyunknown
factThe subject's own site
→ AvlayahCompanyunknown
factThe subject's own site
→ AmvuttraCompanyunknown
factThe subject's own site
→ obexelimabCompanyunknown
factThe subject's own site
→ ImdelltraCompanyunknown
factThe subject's own site
→ RasonqueCompanyunknown
factThe subject's own site
→ litifilimabCompanyunknown
factThe subject's own site
→ RyteloCompanyunknown
factThe subject's own site
→ NiktimvoCompanyunknown
factThe subject's own site
→ deucrictibantCompanyunknown
factThe subject's own site
→ YorvipathCompanyunknown
factThe subject's own site
and 33 more

Firm member (1)

→ RpFirmAnchor adviser
factDFX's own graph

Employs (8)

→ Pablo Gerardo LegorretaPersonChief Executive Officer And Managing Member
Aug 1, 2003 to presentfactForm ADV
→ Marshall Jonathan UristPersonExecutive Vice President, Head Of Research And Investments
Apr 1, 2022 to presentfactForm ADV
→ Eric Cornelius SchneiderPersonChief Technology Officer
Sep 1, 2023 to presentfactForm ADV
→ Arthur Richard McgivernPersonExecutive Vice President And General Counsel
Oct 1, 2022 to presentfactForm ADV
→ Carolyn Judith RubinPersonChief Compliance Officer
Mar 1, 2022 to presentfactForm ADV
→ Terrance Patrick CoynePersonChief Financial Officer
Mar 1, 2019 to presentfactForm ADV
→ Douglas ErbPersonChief Administrative Officer
Dec 1, 2014 to presentfactForm ADV
→ George LloydPersonExecutive Vice President And Chief Legal Officer
Jul 1, 2011 to presentfactForm ADV

Manages (8)

→ RPI Intermediate Finance TrustFundPrivate Equity Fund
Apr 29, 2021 to presentfactForm ADV
→ RPI International Holdings 2019, LPFundPrivate Equity Fund
Mar 27, 2020 to presentfactForm ADV
→ RPI US Partners 2019, LPFundPrivate Equity Fund
Mar 27, 2020 to presentfactForm ADV
→ Royalty Pharma SelectFundPrivate Equity Fund
Apr 29, 2021 to presentfactForm ADV
→ Royalty Pharma Cayman Holdings 2008, LPFundHedge Fund
Feb 15, 2012 to presentfactForm ADV
→ Royalty Pharma US Partners LPFundHedge Fund
Feb 15, 2012 to presentfactForm ADV
→ Royalty Pharma US Partners 2008, LPFundHedge Fund
Feb 15, 2012 to presentfactForm ADV
→ Royalty Pharma Cayman Partners, LPFundHedge Fund
Feb 15, 2012 to presentfactForm ADV

Dated events

23 bookkeeping events (roster, classification and holdings changes) folded below

Occurred
Aug 3, 2026
Firm news
Royalty Pharma appoints Greg Raskin as Senior Vice President, Head of Academic Initiatives
The subject's own siteobserved 3 days ago
Occurred
Jul 22, 2026
Firm news
Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune
The subject's own siteobserved 3 days ago
Occurred
Jan 31, 2024
Person left
James Folmar Reddoch (Executive Vice President) no longer on Schedule A of RP Management, LLC
Form ADVobserved 5 days ago
Occurred
Sep 1, 2023
Person joined
Eric Cornelius Schneider joined Schedule A of RP Management, LLC as Chief Technology Officer
Form ADVobserved 5 days ago
Occurred
Oct 1, 2022
Person joined
Arthur Richard Mcgivern joined Schedule A of RP Management, LLC as Executive Vice President And General Counsel
Form ADVobserved 5 days ago
Occurred
Apr 1, 2022
Person joined
Marshall Jonathan Urist joined Schedule A of RP Management, LLC as Executive Vice President, Head Of Research And Investments
Form ADVobserved 5 days ago
Occurred
Mar 1, 2022
Person joined
Carolyn Judith Rubin joined Schedule A of RP Management, LLC as Chief Compliance Officer
Form ADVobserved 5 days ago
Occurred
Sep 16, 2019
Person left
Susannah Gray (Executive Vice President) no longer on Schedule A of RP Management, LLC
Form ADVobserved 5 days ago
Occurred
Mar 1, 2019
Person joined
Terrance Patrick Coyne joined Schedule A of RP Management, LLC as Chief Financial Officer
Form ADVobserved 5 days ago
Occurred
Mar 31, 2015
Person left
Alexander Kwit (Executive Vice President) no longer on Schedule A of RP Management, LLC
Form ADVobserved 5 days ago
Occurred
Dec 1, 2014
Person joined
Douglas Erb joined Schedule A of RP Management, LLC as Chief Compliance Officer And Chief Administrative Officer
Form ADVobserved 5 days ago
Occurred
Feb 15, 2012
Adviser first adv filing
RP Management, LLC first filed Form ADV in the extract (IA)
Form ADVobserved 5 days ago
Occurred
Jul 1, 2008
Person joined
James Folmar Reddoch joined Schedule A of RP Management, LLC as Executive Vice President
Form ADVobserved 5 days ago

Show 23 bookkeeping events

Occurred
Mar 31, 2026
RP Management, LLC: Private Equity Funds on Form ADV 3 (2024 extract) -> 0 (roster 2026-09-01)
Occurred
Apr 29, 2021
RPI Intermediate Finance Trust first reported on Form ADV by RP Management, LLC (Private Equity Fund), GAV $2,168,253,908
Occurred
Apr 29, 2021
Royalty Pharma Select first reported on Form ADV by RP Management, LLC (Private Equity Fund), GAV $101,087,710
Occurred
Mar 27, 2020
RPI International Partners 2019, LP first reported on Form ADV by RP Management, LLC (Private Equity Fund)
Occurred
Mar 27, 2020
RPI International Holdings 2019, LP first reported on Form ADV by RP Management, LLC (Private Equity Fund)
Occurred
Mar 27, 2020
RPS Biopharma Holdings, LP first reported on Form ADV by RP Management, LLC (Private Equity Fund), GAV $54,378,358
Occurred
Mar 27, 2020
RPI US Partners 2019, LP first reported on Form ADV by RP Management, LLC (Private Equity Fund)
Occurred
Mar 27, 2020
Fund 805-7244215386 no longer reported on Form ADV by RP Management, LLC
Occurred
Mar 29, 2019
Fund 805-6345256202 no longer reported on Form ADV by RP Management, LLC
Occurred
Mar 29, 2018
RPS Biopharma Holdings, L.P. first reported on Form ADV by RP Management, LLC (Private Equity Fund), GAV $100,747,188
Occurred
Mar 29, 2018
RPS Biopharma Investments, LP first reported on Form ADV by RP Management, LLC (Private Equity Fund), GAV $110,768,721
Occurred
Feb 15, 2012
Royalty Pharma Cayman Partners 2008, LP first reported on Form ADV by RP Management, LLC (Hedge Fund), GAV $16,976,836
Occurred
Feb 15, 2012
RPI International Partners, LP first reported on Form ADV by RP Management, LLC (Hedge Fund), GAV $3,608,093,588
Occurred
Feb 15, 2012
Royalty Pharma Cayman Holdings 2008, LP first reported on Form ADV by RP Management, LLC (Hedge Fund), GAV $16,976,836
Occurred
Feb 15, 2012
Royalty Pharma Cayman Holdings, LP first reported on Form ADV by RP Management, LLC (Hedge Fund), GAV $958,889,086
Occurred
Feb 15, 2012
Royalty Pharma Cayman Partners, LP first reported on Form ADV by RP Management, LLC (Hedge Fund), GAV $958,889,086
Occurred
Feb 15, 2012
Royalty Pharma US Partners 2008, LP first reported on Form ADV by RP Management, LLC (Hedge Fund), GAV $23,526,341
Occurred
Feb 15, 2012
Royalty Pharma US Partners LP first reported on Form ADV by RP Management, LLC (Hedge Fund), GAV $278,310,491
Occurred
Feb 15, 2012
RPI US Partners, LP first reported on Form ADV by RP Management, LLC (Hedge Fund), GAV $1,347,756,526
Occurred
Feb 15, 2012
RPI International Partners II, LP first reported on Form ADV by RP Management, LLC (Hedge Fund), GAV $398,562,196
Occurred
Feb 15, 2012
RPI International Holdings, LP first reported on Form ADV by RP Management, LLC (Hedge Fund), GAV $4,006,655,784
Occurred
Feb 15, 2012
RPI Holdings, LP first reported on Form ADV by RP Management, LLC (Hedge Fund), GAV $4,006,655,784
Occurred
Feb 15, 2012
RPI US Partners II, LP first reported on Form ADV by RP Management, LLC (Hedge Fund), GAV $392,533,650

Who to call

the organisation, the role and the published line, with the filing or website that published it; revealed to signed-in accounts

The firm's published line

Revealable: 1 business phone (Form ADV), 1 office address (Form ADV), 1 website (Form ADV) · as of 2026-09-13

Also named here, with no published line of their own (reach them through the firm): Pablo Gerardo Legorreta (Chief Executive Officer And Managing Member), Marshall Jonathan Urist (Executive Vice President, Head Of Research And Investments), Eric Cornelius Schneider (Chief Technology Officer), Arthur Richard Mcgivern (Executive Vice President And General Counsel), Carolyn Judith Rubin (Chief Compliance Officer), Terrance Patrick Coyne (Chief Financial Officer), Douglas Erb (Chief Administrative Officer), George Lloyd (Executive Vice President And Chief Legal Officer).

Who to call is the organisation, the person's role and the line they published themselves: a business phone, office address, website or profile link from Form ADV, Form 13F or their own website, with that source named on every value. The counts above are what a reveal returns; a personal email is rarely published, so most reveals are the firm's line. Never data bought from a provider, never anything personal. Reveals by plan

Provenance